Indication

Loreta is an aromatase inhibitor indicated for:
-- Adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer.
-- Extended adjuvant treatment of postmenopausal women with early breast cancer who have received prior standard adjuvant tamoxifen therapy.

-- First and second-line treatment of postmenopausal women with hormone receptor positive or unknown advanced breast cancer.


Dosage & Administration

Loreta tablets are taken orally without regard to meals.
Recommended dose: 2.5 mg once daily.


Precautions

Use of Letrozole may cause decreases in bone mineral density (BMD). Consideration should be given to monitoring BMD. Updated results from the BMD sub-study demonstrated that at 2 years patients receiving Loreta had a median decrease from baseline of 3.8% in hip BMD compared to a median decrease of 2.0% in the placebo group. The changes from baseline in lumbar spine BMD in Loreta and placebo treated groups were not statistically different.


Product Details


Related Products

Medroxy

Medroxy Progesterone Acetate
Hormone

Leroxy

Levothyroxine Sodium
Hormone

Tibo

Tibolone
Hormone

Remens

Norethisterone
Hormone

Allynol

Allylestrenol
Hormone